Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bowman Cox
US FDA would gain more of the ability it seeks to interdict illicit opioids at the border under legislation proposed by House Energy & Commerce Committee's top Democrat. But would there be collateral damage to the legitimate pharmaceutical industry?
US agency's Office of Pharmaceutical Quality continues to accelerate review and inspection processes, according to its first annual report. Meanwhile, the office's signature quality metrics initiative goes underground.
US House committee requests FDA commissioner to provide a contingency response plan should pressures on China's heparin supply chain trigger more of the economically motivated adulteration that killed scores of US patients in 2008.